Targacept plans $75M fund raising, as it will develop PhII schizophrenia candidate on its own
This article was originally published in Scrip
Executive Summary
Targacept wants offer at least $75 million in stock to fund its clinical-stage product candidates. The move follows a few weeks after the company said it would be moving forward on its own with schizophrenia candidate TC-5619 after a decision by AstraZeneca to bail on its option for the compound..